








Akkaraju, Srinivas - The Wall Street Transcript













































 





































Srinivas  Akkaraju
SRINIVAS AKKARAJU joined the Life Sciences team in the Healthcare Group
at J.P. Morgan Partners, LLC, in April 2001. From October 1998 to April
2001, he was in the Business and Corporate Development Group at
Genentech, Inc., most recently as Senior Manager. There Dr. Akkaraju was
responsible for worldwide partnering activities including technology
access deals, in-licensing of early and late-stage therapeutics, and
out-licensing of Genentech development projects. In addition to his
business development role, he also served for the last year as Project
Team Leader for one of Genentech’s clinical development products. During
this time, Dr. Akkaraju was also a founding member of BioStreet, an
online marketplace for biotech opportunities. Prior to joining Genentech
in 1998, Dr. Akkaraju was a graduate student at Stanford University,
where he earned his MD and PhD in Immunology. Dr. Akkaraju earned his
undergraduate degrees in Biochemistry and Computer Science from Rice
University in 1990.
Related Interviews:Investing In Biotechnology: Srinivas Akkaraju - J.p. Morgan PartnersMay 13, 2003Therapeutic-focused Biotechnology: Srinivas Akkaraju - J.p. Morgan Parters LlcMay 08, 2002







CartLatest NewsJames Abate of Centre Asset Management Sees Consumer Demand Driving New Stock HighsMalcolm E. Polley of Stewart Capital and How to Play the Health Care StocksTimothy Biltz, CEO of Lumos Networks Identifies the Key Component for Future 5G NetworksThe Wall Street Transcript is a completely unique resource for investors and business researchers.Over 20,000 CEO, Equity Analyst and Money Manager InterviewsSubscribe now!Sign Up For Newsletter Weekly email with New In-Depth Interviews


Email: 



Most Popular InterviewsDelivering Long-Term Results with a Risk-Managed Growth FundJames A. Abate Published July 20, 2017 in Investing StrategiesCompanies covered: AMAT JNJ COH RL COG NVDA ADBE ATVI KLAC AMZN NFLX GOOG FB GLW MU 005930 000660 WFM JWN CMG GPS EQT RICE SPLS Buy ($25)Finding Investments with Favorable Risk and Reward OpportunitiesHenry  Beukema Published July 19, 2017 in Investing StrategiesCompanies covered: ORCL MSFT NSRGY AMZN WFM LRLCY AGN LNR Buy ($25)Better Returns and Lower Risk in the Midcap SpaceMalcolm E. Polley Published July 18, 2017 in Investing StrategiesCompanies covered: PRAA HURN FII FL NKE AMZN WFM WBA RAD Buy ($25)Most Popular ReportsWireless Communications & Telecom Published July 14, 2017Buy ($175)Investing Strategies Published July 11, 2017Buy ($175)Investing Strategies Published June 30, 2017Buy ($175) 






Top Company Interviews






Register for a Free Account to gain greater access to
            The Wall Street Transcript right now




CEO INTERVIEWSInterview with the President and CEO: Lumos Networks Corp. (NASDAQ:LMOS)Interview with the Corporate VP of Business Development, Strategy and Investor Relations: DSP Group, Inc. (NASDAQ:DSPG)Interview with the CEO and Director: Tactile Systems Technology, Inc. (NASDAQ:TCMD) 

SECTOR ROUNDTABLESNatural Gas Weighs Heavy On E&P Near-Term ProspectsRoundtable Forum:optimism Despite Uncertainty In For-profit EducationRoundtable Forum:a Shift In Focus To Natural Gas From Oil 

MONEY MANAGER INTERVIEWSDelivering Long-Term Results with a Risk-Managed Growth FundFinding Investments with Favorable Risk and Reward OpportunitiesBetter Returns and Lower Risk in the Midcap Space 

ANALYST INTERVIEWSAnalyzing the Secular Drivers Within Communications Infrastructure and TelecomSatellite Companies Benefiting from Growth in Data TrafficIncreased Focus on Content as Consumers Shift to Digital Consumption 




Subscribe Today!







                Since 1963
                © The Wall Street Transcript 1997-2016
Terms and Conditions
Privacy Policy  
            





https://www.twst.com/wp-admin/admin-ajax.php

Pin It on Pinterest





































Share This





Twitter





Facebook





Google+





Gmail





LinkedIn








































×





Join now for free!
Already a member?






First Name 





Last Name 





Email address *








Create new account
 


or create an account with a social network.

Join with Facebook


Join with Twitter


Join with Google








Username or Email address: *





Password: *






LoginJoin now! | Forgot password?
 


or login using a social network


Log in with Facebook


Log in with Twitter


Log in with Google





















Syros Appoints Srinivas Akkaraju To Its Board Of Directors - TheStreet





























































 

 




















Action Alerts PLUS

Access AAPJim Cramer's Best Stocks for 2017Charitable Trust PortfolioMost Recent Trade Alert25 Investing Rules10 Trading Commandments

Real Money

Access RM25 Rules of InvestingJim Cramer's Best Stocks for 201710 CommandmentsStressed Out StocksCramer's Blog

Cramer
Mad Money
ETFs
Futures
Markets
Much More

BanksBiotechRetailTechPersonal FinanceRetirementFinancial Advisor CenterHow to SpendOptionsFixed IncomeVideo










Privacy Policy|Terms of Use© 1996- TheStreet Inc. All rights reserved
















                                DJIA
                            







                                NASDAQ
                            







                                S&P 500
                            






Market Data updated






Sign In




Your Membership(s)








Your Account





Account Preferences


Alerts


Newsletters







Subscribe





Logout



Subscribe

Access insights and guidance from our Wall Street pros. Find the product that's right for you.
Action Alerts PLUS
Action Alerts OPTIONS
Daily Swing Trade
Income Seeker
Quant Ratings
Real Money
Real Money Pro
Stocks Under $10
Top Stocks
Trifecta Stocks
Real Money Pro Portfolio
Chairman's Club
Compare All 
Chatter on the Street













































 








































Syros Appoints Srinivas Akkaraju To Its Board Of Directors






Business Wire




Jun 12, 2017 8:01 AM EDT













 


















































  Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, today announced the appointment of Srinivas Akkaraju, M.D., Ph.D., to the Company's board of directors.  "Srini is a recognized leader who brings a unique strategic perspective, combining deep scientific knowledge with strong business acumen to help innovative biotechnology companies create value for patients and shareholders," said Nancy Simonian, M.D., Chief Executive Officer of Syros. "His experience and insights will be tremendous assets to Syros as we continue to evolve into a fully integrated biopharmaceutical company driven to delivering medicines that control the expression of disease-driving genes to provide a profound and durable benefit for patients. We are thrilled to welcome Srini to our board."  Dr. Akkaraju has nearly 20 years of investment and operational experience in the life sciences sector. He is a Founder and Managing General Partner at Samsara BioCapital. Prior to founding Samsara BioCapital, he served as a General Partner of Sofinnova Ventures from April 2013 to June 2016, Managing Director of New Leaf Venture Partners from January 2009 to April 2013, and Managing Director of Panorama Capital, a private equity firm that he helped found, from September 2006 to December 2008. Before co-founding Panorama Capital, he was a Partner at J.P. Morgan Partners, and earlier in his career, he was in Business and Corporate Development at Genentech (now a wholly owned member of The Roche Group). Dr. Akkaraju currently serves as chairman of the board of Versartis and as a director of Intercept Pharmaceuticals, Seattle Genetics and aTyr Pharma. Previously, he served on the boards of Barrier Therapeutics, Eyetech Pharmaceuticals, ZS Pharma, Synageva Biopharma Corp. and Amarin Corp. Dr. Akkaraju received an M.D. and a Ph.D. in Immunology from Stanford University and undergraduate degrees in Biochemistry and Computer Science from Rice University.  



 








 































































 











Trending


Billionaire Mark Cuban: The Rise of Technology Will Cause a Lot of Unemployment


Alphabet Has One Business That Could Be Worth 50% of the Company, Jim Cramer Explains


Trump Just Resurrected the Ugly Practice Known as Civil Forfeiture for No Reason


Starbucks Has an Alarming Problem That Even Its Fans Must Admit Has to Be Fixed -- and Soon!


Chipotle Is Doomed Unless It Takes This One Dramatic Measure











Advertising Partners



 






 






 






 


























 

























 































 


©1996-2017 TheStreet, Inc. All rights reserved.Action Alerts PLUS is a registered trademark of TheStreet, Inc.




Compare Brokers



 







 







 







 







 







 














AKKARAJU SRINIVAS: Form 4 Insider Trading History | Insider Insights



 







insider data searchcompliance searchprospect searchmanage portfoliosnew portfoliomanage screensnew screen





Home

About

FAQ

Contact

Media Mentions

Money Management

Subscribe



 










Search









Free Insider Data

Latest Insider Filings
Top 20 Searches
Portfolio Alerts
Top Trades Email
Special Screens Reports



Subscription Insider Data

Insider Filing Search
Prospect Search
Insider Special Screens
Insider Portfolio Alerts
Subscribe To Data Module



Insider Newsletter

Get Latest Newsletter
Subscribe To Newsletter



Subscriber Sign In

Pre-Programmed Screens
Pre-Programmed Searches
Saved Client Screens
Saved Client Searches
Saved Client Dossiers
Subscribe Now
Sign In




















Search by Ticker
Search by Filer Name
Search by Company Name
Search by Input Date



















Transaction Types













 B
 AB
 JB*
 OB
 OE*
 OE


 S
 AS
 JS*
 OS
 OS*
 3








 JB


 JS







					Reduced Version of Subscription Insider Search







Check all filing types




Uncheck all filing types




Remove The Noise























        Free Insider
        Products
    

Insider Portfolio Alerts
Free real time insider alerts


Top Trade Alerts
Free insider trades intra-day


Special Screens Report
Free insider special screens report





	Our Input Date Search is an excellent tool to examine the latest insider trades for new long and short investment ideas, 
	but it is only available to paid subscribers.
	
Click Here to Subscribe

close window



	Feature available to paying subscribers only. Subscriber output is also not separated on different pages, 
	so that print outs and Excel downloads contain all of a search's information.
	
Click Here to Subscribe

close window















Detailed Insider History For:'AKKARAJU SRINIVAS'














click column headers to sort
#
View Form

Insider Statistics

T
N
H
M
S


Insider Title
Company Name
Ticker
Trans Type
Dollar Value
Shares Traded
Trans Date From
Trans Date To
Trans Price From
Trans Price To
Total Holdings
Delta % Owned
Owned
Other Info
SIC Code
SIC Sector
SIC Industry
SIC Sub-Industry
Input Date
1

     
DIR
INTERCEPT PHARMACEUTICALS INC
ICPT
JB
---
1,423
---
6/27/17
---
---
14,669
10.7
D
R
2834
Manufacturing
Chemicals And Allied Products
 Pharmaceutical Preparations
6/29/17 - 9:01:48 pm
2

     
DIR
SYROS PHARMACEUTICALS INC
SYRS
3
---
---
---
6/8/17
---
---
720,720
---
I
---
2834
Manufacturing
Chemicals And Allied Products
 Pharmaceutical Preparations
6/12/17 - 4:02:07 pm
3

     
DIR
VERSARTIS INC
VSAR
JB
---
3,480
---
5/25/17
---
---
14,955
30.3
D
R
2834
Manufacturing
Chemicals And Allied Products
 Pharmaceutical Preparations
6/6/17 - 8:05:10 pm
4

     
DIR
SEATTLE GENETICS INC WA
SGEN
JB
---
3,700
---
5/19/17
---
---
28,505
14.9
D
R
2836
Manufacturing
Chemicals And Allied Products
 Biological Products, (No Disgnostic Substances) 
5/23/17 - 7:08:34 pm
5

1y10%-36%6
DIR
VERSARTIS INC
VSAR
JB*
$7,000,005
571,429
---
3/24/17
---
$12.25
571,429
New
I
---
2834
Manufacturing
Chemicals And Allied Products
 Pharmaceutical Preparations
3/28/17 - 8:06:12 pm
6

1y10%-36%6
DIR
VERSARTIS INC
VSAR
JB*
$7,000,005
571,429
---
10/3/16
---
$12.25
571,429
New
I
---
2834
Manufacturing
Chemicals And Allied Products
 Pharmaceutical Preparations
10/4/16 - 12:41:25 pm
7

     
DIR
INTERCEPT PHARMACEUTICALS INC
ICPT
JB
---
1,204
---
7/19/16
---
---
13,246
10.0
D
R
2834
Manufacturing
Chemicals And Allied Products
 Pharmaceutical Preparations
7/21/16 - 9:04:45 pm
8

     
DIR
VERSARTIS INC
VSAR
JB
---
6,900
---
6/14/16
---
---
11,475
150.8
D
R
2834
Manufacturing
Chemicals And Allied Products
 Pharmaceutical Preparations
6/20/16 - 9:54:50 pm
9

     
DIR
SEATTLE GENETICS INC WA
SGEN
JB
---
3,700
---
5/20/16
---
---
24,805
17.5
D
R
2836
Manufacturing
Chemicals And Allied Products
 Biological Products, (No Disgnostic Substances) 
5/24/16 - 8:05:57 pm
10

1y757%22%6
DIR
INTERCEPT PHARMACEUTICALS INC
ICPT
OB
$32,250
1,500
---
5/13/16
---
$21.50
12,042
14.2
D
---
2834
Manufacturing
Chemicals And Allied Products
 Pharmaceutical Preparations
5/17/16 - 9:00:18 pm
11

     
DIR
ZS PHARMA INC
ZSPH
JS
$90,000
1,000
---
12/17/15
---
$90.00
---
All
D
R
2834
Manufacturing
Chemicals And Allied Products
 Pharmaceutical Preparations
12/21/15 - 6:44:08 pm
12

     
DIR
INTERCEPT PHARMACEUTICALS INC
ICPT
JB
---
650
---
11/24/15
---
---
10,542
6.6
D
R
2834
Manufacturing
Chemicals And Allied Products
 Pharmaceutical Preparations
11/27/15 - 9:02:59 pm
13

1y757%22%6
DIR
INTERCEPT PHARMACEUTICALS INC
ICPT
OB
$26,875
1,250
---
10/28/15
---
$21.50
9,892
14.5
D
---
2834
Manufacturing
Chemicals And Allied Products
 Pharmaceutical Preparations
10/30/15 - 11:59:58 am









Amazon.com Widgets











Subscribe

Search

Screens

Alerts

Newsletter

Money Management

Free Stuff




Home

About

FAQ

Contact

Disclaimer & Terms Of Use

Privacy

Media Mentions

Transaction Codes


© 2017 InsiderInsights.com



 















Akkaraju Srinivas - Insider Stock Trading - OpenInsider











Sector

All Sectors

Group by Sector


Aerospace
Agriculture
Automobile
Building
Business Services
Chemical
Electrical
Energy
Fashion
Financial
Food & Beverage
Fund
Healthcare
Household
Insurance
Machinery
Media
Metals
Mining
Other
Personal Services
Real Estate
Retail
Technology
Telecom
Transportation
Utility




Industry

All Industries

Group by Industry






Insiders
Filings


All
Purchases
Sales

CIK: 1253170 - Address: C/o Intercept Pharmaceuticals, Inc., 10 Hudson Yards, Floor 37, New York, NY 10001 50 results 

						Links
						


SECYahooGoogleFinvizTradingViewStockChartsStockTwitsDownload CSV 













TC
Stat
Stk
Ins
Fil
+d
+w
+m
+q
+h
+y
avg


P%ret41801518202111P%wins75385057575054S%ret21181-31827141011S%wins39786156673956 




Filing Date
T Date
Ticker
IssuerInc Sector
IndIndustry
Owner
oSt
Rel
Title
T
TVal
Price
L
Qty
oc
Own
H
r2y
r1y
r6m
r3m
r6w
r3w
r7d
r3d
f1d
f1w
f1m
f3m
f6m
f1y



3/28/17 20:063/24/17VSARVersartis, Inc.HealthDrugPharmaceutical PreparationsAkkaraju SrinivasCADP7,00012.259571999%583I622361403651552-1-8
10/4/16 12:4110/3/16VSARVersartis, Inc.DEHealthDrugPharmaceutical PreparationsAkkaraju SrinivasCADP7,00012.253571999%583I-3784515-7-4-6-101-122375
5/17/16 21:005/13/16ICPTIntercept Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsAkkaraju SrinivasNYDM.d3221.503321412D-52-56-2613-11-10-2-214724-16
10/30/15 11:5910/28/15ICPTIntercept Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsAkkaraju SrinivasNYDM.d2721.503311410D190-34-35-37-15-9-7-2-597-36-9-25
5/22/15 21:005/19/15ICPTIntercept Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsAkkaraju SrinivasNYDM.d2221.50331139D671226421-54-9-150-21-26-35-48
5/14/15 21:245/12/15LIFEAtyr Pharma IncDEHealthBioPrdBiological Products, (No DiagAkkaraju SrinivasCADHFormer 1P.d4,48014.0017320211,866I2-2128-18-47-91
11/13/14 09:3211/11/14ICPTIntercept Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsAkkaraju SrinivasNYDM.d5421.50333498D676212-42-45-31-29-36-6-3-4-16288812
11/13/14 09:3211/12/14ICPTIntercept Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsAkkaraju SrinivasNYDP.d334167.19332358D676212-42-45-31-29-36-6-3-4-16288812
11/5/14 21:0010/16/14ICPTIntercept Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsAkkaraju SrinivasNYDM.d00.00330113D9994023172321020-28-41-179-23
7/18/14 21:007/16/14ICPTIntercept Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsAkkaraju SrinivasNYDM.d00.00330133D313-25-11-18-12-6-70431-10-3428
4/18/14 21:004/16/14ICPTIntercept Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsAkkaraju SrinivasNYDM.d00.00330172D657299-14-42-24-18-61787-10-1117
3/28/14 18:463/26/14VSARVersartis, Inc.DEHealthDrugPharmaceutical PreparationsAkkaraju SrinivasCADTP.d1,26021.00336032,147D10-5-1-7-33-36
1/17/14 21:011/16/14ICPTIntercept Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsAkkaraju SrinivasNYDM.d5419.033332D724449362390319290-2411026-19-27-52
1/17/14 21:011/16/14ICPTIntercept Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsAkkaraju SrinivasNYDS.d-871267.9433-3-632D724449362390319290-2411026-19-27-52
12/19/13 21:0012/18/13ICPTIntercept Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsAkkaraju SrinivasNYDS-1455.5310-0-102D68481159-4-9915469582376161
10/21/13 06:1310/16/13ICPTIntercept Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsAkkaraju SrinivasNYDM.d00.00140143D183681412-19-7-8-46-11486408316
7/16/13 21:317/16/13ICPTIntercept Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsAkkaraju SrinivasNYDM.d00.0080162D474959281303-1-721633343
6/17/13 19:286/14/13SGENSeattle Genetics Inc /waDEHealthBioPrdBiological Products, (No DiagAkkaraju SrinivasWADM.d428.382455614D683534-2-10-61-31-520502326
6/17/13 19:286/14/13SGENSeattle Genetics Inc /waDEHealthBioPrdBiological Products, (No DiagAkkaraju SrinivasWADS.d-16432.7524-5-2614D683534-2-10-61-31-520502326
5/14/13 09:305/10/13SGENSeattle Genetics Inc /waDEHealthBioPrdBiological Products, (No DiagAkkaraju SrinivasWADM.d22312.76311810D1139961277-3363-4-14134-6
5/14/13 09:305/10/13SGENSeattle Genetics Inc /waDEHealthBioPrdBiological Products, (No DiagAkkaraju SrinivasWADS.d-65037.1731-18-6310D1139961277-3363-4-14134-6
4/17/13 21:314/16/13ICPTIntercept Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsAkkaraju SrinivasNYDM.d00.00101001D-3-15-15-9-7010-15487670
4/11/13 21:334/9/13ICPTIntercept Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsAkkaraju SrinivasNYDM.d00.0010New0D4-10-7-5-2-2-9-104386757
10/16/12 18:0310/16/12ICPTIntercept Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsAkkaraju SrinivasNYDP10,50015.006700New700I1-1137361209
6/28/12 18:016/26/12GEVASynageva Biopharma CorpDEHealthBioPrdBiological Products, (No DiagAkkaraju SrinivasCAHFormer DS.m-13,60239.740-342-251,027I
3/21/12 18:103/19/12GEVASynageva Biopharma CorpDEHealthBioPrdBiological Products, (No DiagAkkaraju SrinivasCADS-11,14132.550-342-201,369I
6/23/10 21:216/21/10SGENSeattle Genetics Inc /waDEHealthBioPrdBiological Products, (No DiagAkkaraju SrinivasWADM.d3687.37105010D3740381-1-5-2-6-2-6-6-72056
8/20/09 14:498/18/09SGENSeattle Genetics Inc /waDEHealthBioPrdBiological Products, (No DiagAkkaraju SrinivasCADP5611.471358910D4-2163132-5-211527-18-12-1
6/29/09 20:446/25/09SGENSeattle Genetics Inc /waDEHealthBioPrdBiological Products, (No DiagAkkaraju SrinivasCADP519.2146New6D-697-512-7223-32645935
9/24/08 15:379/19/08SGENSeattle Genetics Inc /waDEHealthBioPrdBiological Products, (No DiagAkkaraju SrinivasCADS.ad-1,11712.746-88-13604I16312335-44-3-8-5-9-25-25-1619
9/24/08 13:499/18/08SGENSeattle Genetics Inc /waDEHealthBioPrdBiological Products, (No DiagAkkaraju SrinivasCADS.ad-62812.716-49-7618I16312335-44-3-8-5-9-25-25-1619
9/23/08 16:429/22/08SGENSeattle Genetics Inc /waDEHealthBioPrdBiological Products, (No DiagAkkaraju SrinivasCADS.d-23812.796-19-3601I16632433-11012-5-6-22-24-1521
9/22/08 15:299/19/08SGENSeattle Genetics Inc /waDEHealthBioPrdBiological Products, (No DiagAkkaraju SrinivasCADS.d-47212.746-37-12,746I18411334051691-6-12-28-32-2214
9/19/08 14:249/18/08SGENSeattle Genetics Inc /waDEHealthBioPrdBiological Products, (No DiagAkkaraju SrinivasCADS.d-26512.715-21-12,882I1781343321014972-10-31-31-2515
7/30/08 16:007/29/08SGENSeattle Genetics Inc /waDEHealthBioPrdBiological Products, (No DiagAkkaraju SrinivasCADS.d-1,03810.855-96-32,890I18114114213517-2683-24-615
7/29/08 17:097/28/08SGENSeattle Genetics Inc /waDEHealthBioPrdBiological Products, (No DiagAkkaraju SrinivasCADS.d-22010.365-21-12,950I148950142712-7-153-27-410
7/28/08 19:317/25/08SGENSeattle Genetics Inc /waDEHealthBioPrdBiological Products, (No DiagAkkaraju SrinivasCADS.d-1,60110.815-148-52,965I1781216523361675147-17-410
5/19/08 17:285/16/08SGENSeattle Genetics Inc /waDEHealthBioPrdBiological Products, (No DiagAkkaraju SrinivasCADS.d-43710.393-42-13,075I138-3-954-230-3-4-922-2-11
5/19/08 17:275/15/08SGENSeattle Genetics Inc /waDEHealthBioPrdBiological Products, (No DiagAkkaraju SrinivasCADS.d-1,00110.143-99-33,106I138-3-954-230-3-4-922-2-11
5/15/08 12:175/14/08SGENSeattle Genetics Inc /waDEHealthBioPrdBiological Products, (No DiagAkkaraju SrinivasCADS.d-1,22610.103-121-43,179I1337-737-6-323-10-12221-15
5/15/08 12:155/13/08SGENSeattle Genetics Inc /waDEHealthBioPrdBiological Products, (No DiagAkkaraju SrinivasCADS.d-51210.063-51-23,269I1337-737-6-323-10-12221-15
12/12/07 13:2912/10/07SGENSeattle Genetics Inc /waDEHealthBioPrdBiological Products, (No DiagAkkaraju SrinivasCADS.d-26512.636-21-13,307I12283142-692-125-24-25-23-23
6/8/07 21:022/15/05BTRXBarrier Therapeutics IncDEHealthDrugPharmaceutical PreparationsAkkaraju SrinivasCADS.a-9,00818.330-491-83103I
2/14/07 08:302/9/07SGENSeattle Genetics Inc /waDEHealthBioPrdBiological Products, (No DiagAkkaraju SrinivasCADS.d-17,2698.575-2,015-1000I7390128667232-213-5-202136
11/16/05 21:5011/7/05EYETEyetech Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsAkkaraju SrinivasNYDM.d321.4402212,320I
2/17/05 21:292/15/05BTRXBarrier Therapeutics IncDEHealthDrugPharmaceutical PreparationsAkkaraju SrinivasNYDS-9,00818.330-491-75166I
1/4/05 21:3012/30/04BTRXBarrier Therapeutics IncDEHealthDrugPharmaceutical PreparationsAkkaraju SrinivasNYDP1,1687.94014722825I
1/4/05 21:3012/30/04BTRXBarrier Therapeutics IncDEHealthDrugPharmaceutical PreparationsAkkaraju SrinivasNYDS-1,1687.940-147-15825I
10/29/04 17:0510/28/04EYETEyetech Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsAkkaraju SrinivasNYDS.d-41,26041.260-1,000-312,241I
6/4/04 14:426/2/04EYETEyetech Pharmaceuticals IncDEHealthDrugPharmaceutical PreparationsAkkaraju SrinivasNYDS.d-31,19438.500-810-203,241I



DDerivative transaction in filing (usually option exercise)
MMultiple transactions in filing; earliest reported transaction date and weighted average transaction price
AAmended filing
EError detected in filing



S - SaleSale of securities on an exchange or to another person

S - Sale+OESale of securities on an exchange or to another person (after option exercise)

F - TaxPayment of exercise price or tax liability using portion of securities received from the company

P - PurchasePurchase of securities on an exchange or from another person


Return to top
Contact
Copyright © 2017 OpenInsider.com. All rights reserved.






Syros Pharmaceuticals: Srinivas Akkaraju








 







































 








Your browser is blocking javascript. This might limit your experience on this website

 








SUBSCRIBE
FREE NEWSLETTER


Breaking News on Global Pharmaceutical Technology & Manufacturing






 






Ingredients
Drug Delivery
Processing
Regulatory & Safety







Headlines




Ingredients
Drug Delivery
Processing
Regulatory & Safety
Video
Audio
Gallery
Internet Live Events










Site Archive
July 2017
June 2017
Previous months







Hot topics




Bioavailability Challenge 
Globalisation
Lifecycle management
Mergers and acquisitions













Resource Library




APIs (active pharmaceutical ingredients)
Delivery formulations
Delivery technologies
Excipients, raw materials and intermediates
Packaging machinery & supplies


Processing equipment
QA/QC
Regulations
Tabletting, coating & ancillary equipment





Resources
All Products
Supplier Webinars
Videos & Audio
Technical Papers
Product Brochures
Suppliers







Events




All events
Shows & Conferences


Other industry events








On the road




CPhI Worldwide Paris 2014
AAPS 2014 San Diego
TechnoPharm / POWTECH 2014 Nuremberg, Germany
Interphex 2014
AAPS 2013 in San Antonio
CPhI 2013 in Frankfurt
Interphex 2013 in New York
AAPS 2012 in Chicago
CPhI 2012 in Madrid
Achema 2012 in Frankfurt
Interphex 2012 in New York
Interphex 2011 in New York
AAPS 2010 in New Orleans













Related sites




Outsourcing-Pharma.comContract Research, Manufacturing & Clinical Trials  BioPharma-Reporter.comBiopharmaceutical Development & Manufacturing 




















 







Headlines > Regulatory & Safety









Read more breaking news


 



 

 

Text size
Print
Forward


















Subscribe to our FREE newsletter
SUBSCRIBE






Syros Pharmaceuticals: Srinivas Akkaraju



 
 
 




Massachusetts, US-based Syros Pharmaceuticals has appointed Srinivas Akkaraju to the company’s board of directors. The biopharmaceutical firm focuses on the understanding of the non-coding region of the genome, to advance medicines that control expression of disease-driving genes.The company is currently focused on cancer and immune-mediated diseases and is advancing a growing pipeline of gene control medicines.Syros spokesperson Naomi Aoki told in-PharmaTechnologist Akkaraju’s business-focused background will benefit the firm in strategic decision making.“Our goal is to leverage our leadership in gene control to build a fully integrated and enduring company by maximising the promise of our programmes and our platform across disease areas. Along the way, there will be many key strategic decisions around our programs, potential partnerships and financings,” she said.“Srini brings a compelling strategic perspective, combining deep scientific knowledge with strong business acumen. He has a proven track record as an investor and a board member of helping innovative biotechnology companies create value for patients and shareholders, and we believe his experience and expertise will be valuable in helping us navigate many of those important strategic decisions,” Aoki told us.Akkaraju received an MD and PhD in immunology from Standford University.He is founder and managing partner at Samsara BioCapital, was a general partner of Sofinnova Ventures, and managing director of New Leaf Venture Partners and Panorama Capital.He is chairman of the board at Versartis, and a director of Intercept Pharmaceuticals, Seattle Genetics and aTyr Pharma.







Ocugen: Daniel Jorgensen 





Syros Pharmaceuticals: Srinivas Akkaraju 





IGBMA: Ingrid Schwarzenberger 





Boyds: Elaine Harper & Jayne Hunt 





Dragonfly Therapeutics: Nicolai Wagtmann 







1
 |  2
 |  3
 |  4
 |  5






























All Gallery







 Pharma executives make a move: recent appointments  
Ocugen welcomes ex-Pfizer Daniel Jorgensen, the IGBMA’s Biosimilars Committee gets a new chair and drug development consultants...




 Moving up in the world: recent pharma appointments
The US FDA welcomes Scott Gottlieb to the helm, Actinium appoints adult leukaemia expert Richard Stone, and...




 Hiring and Firing Feb '17
in-PharmaTechnologist presents this month's roundup of who is moving where in the Pharma industry.




 Hiring and Firing Jan '17
Welcome to in-PharmaTechnologist's monthly round up of who's been moving where in the small-molecule manufacturing world. The...




 Drug development in space: how microgravity enables pharma
Eli Lilly is conducting several experiments on the International Space Station (ISS) US National Laboratory over the...








  







Most Popular News



1Merck unveils EU plant cuts and consolidation plan citing Sigma's US strategy2Mylan's EU biosimilar ambition hit by GMP issues at Biocon plant3Vaccine booster for France, big pharma prepared4US FDA warns Vista Pharmaceuticals about Telangana plant 5Concerns raised about Italy and Greece as backdoors into the FMD protected meds markets


  







Key Industry Events







 

Access all events listing
Our events, Shows & Conferences...













Products





 

Influence of Different Lubricants on Tableting Characteristics and Dissolution Behavior
JRS Pharma
 


The Solid Dose, Latest News from Colorcon
Colorcon Inc. 
 


Increase tablet production with multi-tip tools
I Holland Limited 
 

View All Products










Today's Headlines






 GSK says UK manufacturing cuts not Brexit related
 
 The serialisation stragglers: industry concern for complacency 
 
 WHO prequalifies Mylan's India unit to supply TB drug API 
 
 EU to probe if drug firms' pre-submission meetings sway EMA approval decisions
 
 US FDA reaffirms hold on oral Proellex trials prompting Repros rethink
 
 US FDA warns opthalmic supplier Tubilux about Italian plant 





 







Weekly / Daily Free Newsletters
in-PharmaTechnologist.comOutsourcing-Pharma.comBioPharma-Reporter.com  
Pharmaceutical Technology - Daily


Pharmaceutical Outsourcing - Daily


Biopharmaceutical Development - Daily

  
Pharmaceutical Technology - Weekly


Pharmaceutical Outsourcing - Weekly


Biopharmaceutical Development - Weekly

  
     
    

     
    

     
    
  
APIs (active pharmaceutical ingredients)


Analytical testing, QC


Analytical (technologies & services)

  
Delivery formulations


Contract Manufacturing


Bio-Outsourcing

  
Delivery technologies


Drug delivery, formulation


Bioreactors

  
Excipients, raw materials and intermediates


Fill & finish, packaging


Cell lines

  
Processing equipment


Medical Devices


Disposable Manufacturing Tech

  
QA/QC


Phase I-II


Facilities

  
Regulations


Phase III-IV


Fill-Finish & Packaging

  
Tabletting, coating & ancillary equipment


Preclinical


Separation & Purification

  
     
    

Regulatory affairs


     
    
  
     
    

Supply chain, logistics


     
    



Other Newsletters

Pharma legislationPharma financeClinical ResearchDrug targeting and delivery




Subscribe to our FREE newsletterSUBSCRIBE







 Related Sites from our Team


Contract Research, Manufacturing & Clinical Trials
                                             | 
                                                                                    Biopharmaceutical Development & Manufacturing





About us |
                        Site map |
        All sites |
                                            Recommend this Site |
                
                    Advertise |
                            Contact the Editor |
        
        Terms & Conditions  |
        Privacy & Cookie Policy

































Srinivas Akkaraju Turns Over New Leaf - PE Hub























































SUBSCRIBE TO PE HUB WIRE
Join over 60,000 of your peers
Get the must-read email for PE/VC professionals delivered to your inbox daily
        — for free!







US Edition (daily)



Canada Edition (weekly)


We will not send you spam, and we don't share your email address with 3rd parties.


I accept the Terms and Conditions




SUBSCRIBE YES! No






RegisterSign in



A Community for Professionals in Private Capital



































Srinivas Akkaraju Turns Over New Leaf


January 22, 2009
By PEHub Administrator






Srinivas Akkaraju has joined New Leaf Venture Partners as a managing director and head of the firm’s West Coast biopharma practice. He previously was a co-founder and managing director of Panorama Capital.
PRESS RELEASE
New Leaf Venture Partners (NLV Partners) announced today the appointment of Srinivas Akkaraju, M.D., Ph.D., as Managing Director and lead of NLV Partners’ West Coast biopharmaceuticals practice. Dr. Akkaraju’s appointment is effective immediately. 
 
“Dr. Akkaraju will be a tremendous addition to NLV Partners, and we are delighted to welcome him to the team,” stated Philippe Chambon, M.D., Ph.D., Managing Director of NLV Partners. “We expect his broad network of contacts and extensive experience in the biopharma industry will prove invaluable for the firm and to our portfolio companies, particularly on the West Coast.”  





 
Dr. Akkaraju commented, “I am excited to join NLV Partners. The depth, quality and cohesiveness of NLV Partners attracted me to the firm, and I look forward to the opportunity to continue developing as an investor in a dynamic and creative environment.” 
 
Dr. Akkaraju brings over 11 years of experience in life sciences investing and business development. Prior to joining NLV Partners, Dr. Akkaraju was a co-founder and Managing Director of Panorama Capital. Before forming Panorama, Dr. Akkaraju served as Partner of J.P. Morgan Partners, LLC, where he was responsible for leading venture investing in biotech companies. Previously, Dr. Akkaraju held business and corporate development positions at Genentech, where he was responsible for worldwide partnering activities, in-licensing of therapeutics and out-licensing of development projects. In addition, Dr. Akkaraju was a founding member of BioStreet, an online marketplace for biotech opportunities. 
  





Dr. Akkaraju currently serves on the Board of Directors of Amarin Corporation, Seattle Genetics and Pharmos Corporation, as well as several private companies. He is the author of a number of peer-reviewed articles, including in Science and Nature. He received B.A. degrees in both Biochemistry and Computer Science from Rice University and M.D. and Ph.D. degrees in Immunology from Stanford University School of Medicine. 
 
About NLV Partners 
 
NLV Partners is a life science-dedicated venture capital firm with offices in Menlo Park and New York. Founded by an experienced team of venture capitalists with deep healthcare industry experience, NLV Partners invests primarily in companies focused on clinical-stage biopharmaceutical products, early-stage medical devices and molecular diagnostics. NLV Partners manages over $1.3 billion of assets, including NLV-I, NLV-II and the healthcare technology portfolio of Sprout Group. For further information, visit the NLV Partners website at www.nlvpartners.com.  





Take your pick!

Buyouts delivers exclusive news and analysis about private equity deals, fundraising, top-quartile managers and more. Get your FREE trial or subscribe now.
VC Journal provides exclusive news and analysis about venture capital deals, fundraising, top-quartile investors and more. Get your FREE trial or subscribe now. 
 









Sign up to our Newsletter

Receive updates from our PE HUB Wire and Top Stories of the Week newsletters:


First Name:



Last Name:



Email Address:




US Edition (daily)



Canada Edition (weekly)


We will not send you spam, and we don't share your email address with 3rd parties.


I accept the Terms and Conditions









You are now subscribed to the PEHub Wire and Top Stories of the Week newsletters. 




Buyouts Insider/Argosy Group LLC produces several free newsletters that are sent directly to the email you provide at registration (namely, PE Hub Wire, PE Hub Canada Wire, PE Hub Wire Top Story of the Week, Buyouts Daily, and VCJ Alert). To enable us to keep providing these services free of charge, we reserve the right to contact you with special invitations to sample or purchase private equity-related products. 
By submitting this free subscription request for any of these products, you are also consenting to this communication. Should you ever wish to unsubscribe from a particular communication you may activate the unsubscribe mechanism at the bottom of the email. This will discontinue both the special invitations mentioned previously, as well as your subscription to the weekly newsletter. The information you provide will be safeguarded by Argosy Group LLC/Buyouts Insider. The company’s subsidiaries may use it to keep you informed of relevant products and services. We occasionally allow reputable companies outside of the company to mail details of products which may be of interest to you. As an international group, we may transfer your data on a global basis for the purposes indicated above. 
WE WILL NEVER SHARE YOUR EMAIL OR CONTACT DETAILS WITH ANY OUTSIDE COMPANY HOWEVER.

			    Should you have any questions please do not hesitate to contact us: [email protected].
	    	

 




Top Posts New oil and gas company Native racks up $140 mln
by Iris Dorbian

Bain Capital Double Impact funds two companies
by Iris Dorbian

MidOcean to sell Water Pik for $1 bln
by Luisa Beltran

Carlyle to invest in ZeroChaos
by Luisa Beltran

Awake Security nabs over $30 mln from Greylock and Bain Capital Ventures
by Iris Dorbian

Thoma Bravo to sell Sparta Systems to New Mountain
by Iris Dorbian

The PE HUB Podcast, Episode Two
by Staff Report

Post Capital sells BHS Specialty Chemicals
by Iris Dorbian

 





























 



Srinivas Akkaraju, Managing Director, Seattle Genetics, Inc. | Spoke











































LOGIN



REGISTER








Add Company



Add Person



Add Topic




Login






Or



















Home | People | Srinivas Akkaraju


Advanced Search
FAQ




Javascript is disabled












Bio
EDIT













Srinivas Akkaraju

Srinivas D.



Managing Director, Seattle Genetics, Inc.




Bothell, WA




Find other people named Srinivas Akkaraju




General Info


Biological Product (except Diagnostic) Manufacturing



Add Tags— eg, Finance, Business2Business...



Back to Top
 Srinivas Akkaraju,M.D., Ph.D.,has served as a Director of Seattle Genetics since July 2003. Dr. Akkaraju is a Managing Director at Panorama Capital. Previously, he was with J.P. Morgan Partners, serving as a Principal starting in April 2001 and becoming a Partner in January 2005. From October 1998 to April 2001, he was in Business and Corporate Development at Genentech, Inc., most recently as Senior Manager. Prior to joining Genentech, Dr. Akkaraju was a graduate student at Stanford University, where he earned his M.D. and a Ph.D. in Immunology. He received his undergraduate degrees in Biochemistry and Computer Science from Rice University. He is also a director of Barrier Therapeutics.


Not who you're looking for?
Find other Srinivas Akkarajus on Spoke




Contact



Telephone



Email



Background Report



Public Records


powered by





Digital Info



www.seattlegenetics.com



N/A



N/A



N/A



N/A



N/A



N/A









Resume

EDIT
CAREER



Seattle Genetics, Inc.

Managing Director





EDUCATION

EDIT

Add a Degree— eg, Bachelors in Business Administration








Blogs By Industry Voices


There are currently no Blogs by Industry Voices





Achievements and Recognition
EDIT


Add an achievement and/or recognition— eg, Man of the year, Forbes 2011...





Notable Links

EDIT


The links below are powered by Bing search results. Click edit to customize.





Videos
EDIT


Add a videofrom youtube or vimeo





EXECUTIVES & FEATURED PEOPLE AT Seattle Genetics, Inc.








Daniel Hoth

President









Todd Simpson

Chief Financial Officer









Paul Carter

Vice President









Eric Dobmeier

Cbo









Clay Siegall

President and Chief Executive Officer









Ken Realmuto

Contract Recruiter









Kirsten Smith

Senior Director,Human Resources
















Created on Jun 06, 2011


by Spoke
 







Edited on Jun 06, 2011


by Spoke
 




PAGE COMPLETION

40%




Summary




Career




Website/Blog




Industry




Add a Photo



Add 3 Notable Links



Add 3 Achievements



Add Education



Add a Video



Add a Social Network



View More


View Less



SHARE THIS PAGE
















Add Page


Add Company
Add Person
Add Topic




Copy this code to embed a widget:



<div id="spoke-root"></div>
<script>(function(d, s, id) {
var js, sjs = d.getElementsByTagName(s)[0];
if (d.getElementById(id)) return;
js = d.createElement(s); js.id = id;
js.src = "//www.spoke.com/assets/widget.js";
sjs.parentNode.insertBefore(js, sjs);
}(document, 'script', 'spoke-widget-js'));</script>
    <div class="spoke-widget" data-host="//www.spoke.com" data-type="person" data-id="3e1429c09e597c100372f7e0" data-width="404" data-height="230" data-scroll="no" data-frame-border="none"></div>
    <div style="font-size: 9pt;"><a href="http://www.spoke.com/people/srinivas-akkaraju-3e1429c09e597c100372f7e0">Srinivas Akkaraju</a> widget provided by <a href="http://www.spoke.com">Spoke</a></div>




Public Records
Our partner can help you find public records for Srinivas.


More on









Some of Spoke's Content Providers








Become a Spoke Content Provider
Learn More





ICPT Srinivas Akkaraju Insider Trades for Intercept Pharmaceuticals Inc.


































Bulletin






Investor Alert







Tokyo Markets Open in:



US Market Snapshot
Currencies
Commodities


















Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close































Intercept Pharmaceuticals Inc.

                  NASDAQ: ICPT
          



GO



Set Alerts
Find a Broker




Join TD Ameritrade




Market Index


 

Overview
      
Profile
      
News
      
Charts
      
Financials
      
Historical Quotes
      
Analyst Estimates
      
Options
      
SEC Filings
      
Insiders
      


/marketstate/country/us

Intercept Pharmaceuticals Inc.



After Hours
 --Quotes are delayed by 20 min
Jul 21, 2017, 4:48 p.m.


ICPT

/quotes/zigman/12230574/composite


$
128.15




Change

+0.75
+0.59%

Volume
Volume 2,512
Quotes are delayed by 20 min








/quotes/zigman/12230574/composite
Previous close

$
			128.66
		


$
				127.40
			
Change

-1.26
-0.98%





Day low
Day high
$127.14
$129.34










52 week low
52 week high

            $96.63
        

            $177.93
        


















Insider Activity


Individual




Srinivas Akkaraju



Dr. Srini Akkaraju, MD PhD, is General Partner at Sofinnova Ventures, Inc. He also serves on several boards.
Prior to joining Sofinnova Ventures in 2013, Dr. Akkaraju was a Managing Director at New Leaf Venture Partners. Prior to NLVP, he was a co-founder and Managing Director at Panorama Capital. Before forming Panorama, he served as Partner of J.P. Morgan Partners. Prior to J.P. Morgan Partners, Srini held business and corporate development positions at Genentech.
Dr. Akkaraju received B.A. degrees in both Biochemistry and Computer Science from Rice University and M.D. and Ph.D. degrees in Immunology from Stanford University School of Medicine.



Transactions


Date
Shares
Transaction
Value





06/27/2017
1,423


 
Award at $0 per share.


0


07/19/2016
1,204


 
Award at $0 per share.


0


05/13/2016
1,500


 
Derivative/Non-derivative trans. at $21.5 per share.


32,250


11/24/2015
650


 
Award at $0 per share.


0


10/28/2015
1,250


 
Derivative/Non-derivative trans. at $21.5 per share.


26,875


05/19/2015
1,000


 
Derivative/Non-derivative trans. at $21.5 per share.


21,500


11/12/2014
500


 
Acquisition at $163.27 per share.


81,635


11/12/2014
1,000


 
Acquisition at $173.67 per share.


173,670


11/12/2014
500


 
Acquisition at $158.18 per share.


79,090


11/11/2014
2,500


 
Derivative/Non-derivative trans. at $21.5 per share.


53,750


10/16/2014
324


 
Derivative/Non-derivative trans. at $0 per share.


0


07/17/2014
226


 
Award at $0 per share.


0


07/16/2014
325


 
Derivative/Non-derivative trans. at $0 per share.


0


04/16/2014
324


 
Derivative/Non-derivative trans. at $0 per share.


0


01/16/2014
3,250


 
Disposition at $267.94 per share.


870,805


01/16/2014
2,500


 
Derivative/Non-derivative trans. at $21.5 per share.


53,750


01/16/2014
325


 
Derivative/Non-derivative trans. at $0 per share.


0


12/18/2013
260


 
Disposition at $55.53 per share.


14,438


10/16/2013
324


 
Derivative/Non-derivative trans. at $0 per share.


0


07/16/2013
325


 
Derivative/Non-derivative trans. at $0 per share.


0


05/07/2013
1,330


 
Award at $0 per share.


0


04/16/2013
324


 
Derivative/Non-derivative trans. at $0 per share.


0


04/09/2013
325


 
Derivative/Non-derivative trans. at $0 per share.


0





        Copyright 2017 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
    











            Officers and Executives
        





Dr. Mark E. Pruzanski 
President, Chief Executive Officer & Director




Mr. Jerome B. Durso 
Chief Operating Officer




Mr. Sandip S. Kapadia 
Chief Financial Officer




Dr. David A. Shapiro 
Chief Medical Officer & Executive VP-Development




Mr. Richard  Kim 
Senior Vice President-Commercial Head of US




Dr. Juan Carlos  Lopez-Talavera 
Senior Vice President-Head Medical Affairs




Ms. Lisa  Bright 
President-International




Dr. Rachel L. McMinn 
Chief Business & Strategy Officer




Mr. Christopher  Frates 
Media Contact




Dr. Mark J. Vignola 
Director-Investor Relations




Mr. Paolo  Fundarò 
Chairman




Dr. Keith M. Gottesdiener 
Independent Director




Mr. Daniel Mark Bradbury 
Independent Director




Mr. Daniel G. Welch 
Independent Director




Mr. Gino  Santini 
Independent Director




Dr. Luca  Benatti 
Independent Director




Mr. Glenn P. Sblendorio 
Independent Director




Dr. Srinivas  Akkaraju 
Independent Director









Trending Tickers


/quotes/zigman/17636479/composite VUZI+15.60%


/quotes/zigman/237947/composite JCP-5.83%


/quotes/zigman/59392505/composite NUGT-2.93%


/quotes/zigman/59386294/composite JNUG-5.94%


/quotes/zigman/65801738/composite TLT+1.11%


X




Powered by














Log In




6:24 PM EDT
July 23, 2017


/marketstate/country/us
New York

	Closed


/marketstate/country/uk
London

	Closed


/marketstate/country/jp
Tokyo

	Closed





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
5:37pAt least 9 dead after overheated tractor-trailer found outside Texas Walmart
5:01p‘Full transparency’ doesn’t mean what Scaramucci apparently thinks it means
5:00pStocks brace for volatility in earnings deluge; Fed meeting looms
4:53pThe dark side of cruises
4:53pIf you suddenly quit your job like Sean Spicer, here’s what you should do next
4:52pJohn McCain is a war hero — but think twice before saying he’s ‘battling’ cancer 
4:52pNever (ever) say these things to a co-worker
4:51pMy uncle with dementia needs long-term care — should I refinance his house?
4:49pThis is the deadliest time of your life to put on weight
4:46p5 easily avoidable reasons why millennials can’t have nice things (or save any money)
4:45pWhy house prices in gay neighborhoods are soaring
4:45pNearly 40% of adults don’t have life insurance — these startups are trying to change that
4:44pMarie Kondo says this one thing could be holding you back from falling in love
4:44pThis luxury credit card is only for truly big spenders
4:44pHow Elon Musk and shorter commutes could transform people’s lives
4:43pBanks have raised credit-card interest rates — but not savings account rates
4:43pThe most expensive city in the world is NOT New York or San Francisco
4:42p1 in 10 Americans say they will die in debt
4:40pShopping at Costco, and 5 other things that prove rich people are cheap
12:13aHeavy showers swamp New Orleans street with rainwater
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,580.07

-31.71
-0.15%





nasdaq

/quotes/zigman/12633936/realtime
6,387.75

-2.25
-0.04%





s&p 500

/quotes/zigman/3870025/realtime
2,472.54

-0.91
-0.04%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15

























































403 - Forbidden: Access is denied.



Server Error


403 - Forbidden: Access is denied.
You do not have permission to view this directory or page using the credentials that you supplied.




